rs144915346

Variant summary

Our verdict is Likely benign. The variant received -4 ACMG points: 0P and 4B. BP4_Strong

The NM_014844.5(TECPR2):​c.1981G>A​(p.Glu661Lys) variant causes a missense change. The variant allele was found at a frequency of 0.00139 in 1,613,406 control chromosomes in the GnomAD database, including 1 homozygotes. In-silico tool predicts a benign outcome for this variant. 15/22 in silico tools predict a benign outcome for this variant. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars).

Frequency

Genomes: 𝑓 0.00062 ( 0 hom., cov: 32)
Exomes 𝑓: 0.0015 ( 1 hom. )

Consequence

TECPR2
NM_014844.5 missense

Scores

3
16

Clinical Significance

Conflicting classifications of pathogenicity criteria provided, conflicting classifications U:9B:2

Conservation

PhyloP100: 3.62

Publications

3 publications found
Variant links:
Genes affected
TECPR2 (HGNC:19957): (tectonin beta-propeller repeat containing 2) The protein encoded by this gene is a member of the tectonin beta-propeller repeat-containing (TECPR) family, and contains both TECPR and tryptophan-aspartic acid repeat (WD repeat) domains. This gene has been implicated in autophagy, as reduced expression levels of this gene have been associated with impaired autophagy. Recessive mutations in this gene have been associated with a hereditary form of spastic paraparesis (HSP). HSP is characterized by progressive spasticity and paralysis of the legs. There is also some evidence linking mutations in this gene with birdshot chorioretinopathy (BSCR), which results in inflammation of the choroid and retina. Alternative splicing results in multiple transcript variants encoding different isoforms. [provided by RefSeq, Aug 2015]
TECPR2 Gene-Disease associations (from GenCC):
  • hereditary spastic paraplegia 49
    Inheritance: AR Classification: STRONG, SUPPORTIVE Submitted by: Orphanet, Labcorp Genetics (formerly Invitae), G2P

Genome browser will be placed here

ACMG classification

Classification was made for transcript

Our verdict: Likely_benign. The variant received -4 ACMG points.

BP4
Computational evidence support a benign effect (MetaRNN=0.018195063).

Transcripts

RefSeq

Gene Transcript HGVSc HGVSp Effect Exon rank MANE Protein UniProt
TECPR2NM_014844.5 linkc.1981G>A p.Glu661Lys missense_variant Exon 9 of 20 ENST00000359520.12 NP_055659.2 O15040-1
TECPR2NM_001172631.3 linkc.1981G>A p.Glu661Lys missense_variant Exon 9 of 17 NP_001166102.1 O15040-2

Ensembl

Gene Transcript HGVSc HGVSp Effect Exon rank TSL MANE Protein Appris UniProt
TECPR2ENST00000359520.12 linkc.1981G>A p.Glu661Lys missense_variant Exon 9 of 20 1 NM_014844.5 ENSP00000352510.7 O15040-1
TECPR2ENST00000558678.1 linkc.1981G>A p.Glu661Lys missense_variant Exon 9 of 17 1 ENSP00000453671.1 O15040-2
TECPR2ENST00000560060.5 linkn.-41G>A upstream_gene_variant 4

Frequencies

GnomAD3 genomes
AF:
0.000618
AC:
94
AN:
152204
Hom.:
0
Cov.:
32
show subpopulations
Gnomad AFR
AF:
0.000289
Gnomad AMI
AF:
0.00
Gnomad AMR
AF:
0.000131
Gnomad ASJ
AF:
0.00
Gnomad EAS
AF:
0.00
Gnomad SAS
AF:
0.00
Gnomad FIN
AF:
0.00
Gnomad MID
AF:
0.00
Gnomad NFE
AF:
0.00116
Gnomad OTH
AF:
0.000478
GnomAD2 exomes
AF:
0.000628
AC:
157
AN:
249836
AF XY:
0.000650
show subpopulations
Gnomad AFR exome
AF:
0.000250
Gnomad AMR exome
AF:
0.000289
Gnomad ASJ exome
AF:
0.00
Gnomad EAS exome
AF:
0.00
Gnomad FIN exome
AF:
0.00
Gnomad NFE exome
AF:
0.00120
Gnomad OTH exome
AF:
0.00115
GnomAD4 exome
AF:
0.00147
AC:
2152
AN:
1461084
Hom.:
1
Cov.:
31
AF XY:
0.00138
AC XY:
1001
AN XY:
726830
show subpopulations
African (AFR)
AF:
0.000179
AC:
6
AN:
33478
American (AMR)
AF:
0.000313
AC:
14
AN:
44722
Ashkenazi Jewish (ASJ)
AF:
0.00
AC:
0
AN:
26136
East Asian (EAS)
AF:
0.00
AC:
0
AN:
39700
South Asian (SAS)
AF:
0.00
AC:
0
AN:
86248
European-Finnish (FIN)
AF:
0.000114
AC:
6
AN:
52646
Middle Eastern (MID)
AF:
0.00
AC:
0
AN:
5768
European-Non Finnish (NFE)
AF:
0.00186
AC:
2068
AN:
1111998
Other (OTH)
AF:
0.000960
AC:
58
AN:
60388
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.480
Heterozygous variant carriers
0
160
319
479
638
798
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance

Age Distribution

Exome Het
Exome Hom
Variant carriers
0
92
184
276
368
460
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
GnomAD4 genome
AF:
0.000617
AC:
94
AN:
152322
Hom.:
0
Cov.:
32
AF XY:
0.000550
AC XY:
41
AN XY:
74480
show subpopulations
African (AFR)
AF:
0.000289
AC:
12
AN:
41584
American (AMR)
AF:
0.000131
AC:
2
AN:
15308
Ashkenazi Jewish (ASJ)
AF:
0.00
AC:
0
AN:
3470
East Asian (EAS)
AF:
0.00
AC:
0
AN:
5180
South Asian (SAS)
AF:
0.00
AC:
0
AN:
4826
European-Finnish (FIN)
AF:
0.00
AC:
0
AN:
10610
Middle Eastern (MID)
AF:
0.00
AC:
0
AN:
294
European-Non Finnish (NFE)
AF:
0.00116
AC:
79
AN:
68024
Other (OTH)
AF:
0.000473
AC:
1
AN:
2114
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.504
Heterozygous variant carriers
0
6
12
17
23
29
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance

Age Distribution

Genome Het
Variant carriers
0
2
4
6
8
10
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
Alfa
AF:
0.000913
Hom.:
0
Bravo
AF:
0.000638
TwinsUK
AF:
0.00297
AC:
11
ALSPAC
AF:
0.00104
AC:
4
ESP6500AA
AF:
0.00
AC:
0
ESP6500EA
AF:
0.000814
AC:
7
ExAC
AF:
0.000610
AC:
74
EpiCase
AF:
0.000981
EpiControl
AF:
0.00136

ClinVar

Significance: Conflicting classifications of pathogenicity
Submissions summary: Uncertain:9Benign:2
Revision: criteria provided, conflicting classifications
LINK: link

Submissions by phenotype

Hereditary spastic paraplegia 49 Uncertain:4
Apr 16, 2020
Natera, Inc.
Significance:Uncertain significance
Review Status:no assertion criteria provided
Collection Method:clinical testing

- -

Sep 27, 2022
Labcorp Genetics (formerly Invitae), Labcorp
Significance:Uncertain significance
Review Status:criteria provided, single submitter
Collection Method:clinical testing

This sequence change replaces glutamic acid, which is acidic and polar, with lysine, which is basic and polar, at codon 661 of the TECPR2 protein (p.Glu661Lys). This variant is present in population databases (rs144915346, gnomAD 0.1%), and has an allele count higher than expected for a pathogenic variant. This missense change has been observed in individual(s) with clinical features of TECPR2-related conditions (Invitae). ClinVar contains an entry for this variant (Variation ID: 408916). Algorithms developed to predict the effect of missense changes on protein structure and function (SIFT, PolyPhen-2, Align-GVGD) all suggest that this variant is likely to be tolerated. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. -

Jan 13, 2021
Revvity Omics, Revvity
Significance:Uncertain significance
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

Nov 26, 2018
Baylor Genetics
Significance:Uncertain significance
Review Status:criteria provided, single submitter
Collection Method:clinical testing

This variant was determined to be of uncertain significance according to ACMG Guidelines, 2015 [PMID:25741868]. -

not provided Uncertain:2Benign:1
Nov 01, 2024
CeGaT Center for Human Genetics Tuebingen
Significance:Likely benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

TECPR2: BP4 -

Aug 24, 2022
GeneDx
Significance:Uncertain significance
Review Status:criteria provided, single submitter
Collection Method:clinical testing

In silico analysis supports that this missense variant does not alter protein structure/function; Has not been previously published as pathogenic or benign in association with a TECPR2-related disorder to our knowledge; This variant is associated with the following publications: (PMID: 33206719) -

Dec 09, 2020
Mayo Clinic Laboratories, Mayo Clinic
Significance:Uncertain significance
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

not specified Uncertain:1
Feb 26, 2022
Women's Health and Genetics/Laboratory Corporation of America, LabCorp
Significance:Uncertain significance
Review Status:criteria provided, single submitter
Collection Method:clinical testing

Variant summary: TECPR2 c.1981G>A (p.Glu661Lys) results in a conservative amino acid change in the encoded protein sequence. Four of five in-silico tools predict a benign effect of the variant on protein function. The variant allele was found at a frequency of 0.00063 in 249836 control chromosomes. This frequency is not significantly higher than estimated for a pathogenic variant in TECPR2 causing Hereditary Spastic Paraplegia, Type 49 (0.00063 vs 0.0011), allowing no conclusion about variant significance. To our knowledge, no occurrence of c.1981G>A in individuals affected with Hereditary Spastic Paraplegia, Type 49 and no experimental evidence demonstrating its impact on protein function have been reported. Four clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar after 2014 without evidence for independent evaluation. All laboratories classified the variant as uncertain significance. Based on the evidence outlined above, the variant was classified as uncertain significance. -

Inborn genetic diseases Uncertain:1
Apr 17, 2023
Ambry Genetics
Significance:Uncertain significance
Review Status:criteria provided, single submitter
Collection Method:clinical testing

The c.1981G>A (p.E661K) alteration is located in exon 9 (coding exon 8) of the TECPR2 gene. This alteration results from a G to A substitution at nucleotide position 1981, causing the glutamic acid (E) at amino acid position 661 to be replaced by a lysine (K). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. -

Hereditary spastic paraplegia Uncertain:1
Nov 25, 2020
Genome Diagnostics Laboratory, The Hospital for Sick Children
Significance:Uncertain significance
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

See cases Benign:1
Dec 25, 2019
Laboratorio de Genetica e Diagnostico Molecular, Hospital Israelita Albert Einstein
Significance:Likely benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

ACMG classification criteria: BP1, BP4 -

Computational scores

Source: dbNSFP v4.3

Name
Calibrated prediction
Score
Prediction
AlphaMissense
Benign
0.084
BayesDel_addAF
Benign
-0.42
T
BayesDel_noAF
Benign
-0.39
CADD
Benign
19
DANN
Uncertain
0.99
DEOGEN2
Benign
0.014
T;.
Eigen
Benign
-0.38
Eigen_PC
Benign
-0.32
FATHMM_MKL
Uncertain
0.78
D
LIST_S2
Benign
0.81
T;T
M_CAP
Benign
0.014
T
MetaRNN
Benign
0.018
T;T
MetaSVM
Benign
-1.0
T
MutationAssessor
Benign
1.1
L;L
PhyloP100
3.6
PrimateAI
Benign
0.29
T
PROVEAN
Benign
-2.0
N;N
REVEL
Benign
0.095
Sift
Benign
0.035
D;D
Sift4G
Uncertain
0.036
D;D
Polyphen
0.24
B;.
Vest4
0.33
MVP
0.068
MPC
0.43
ClinPred
0.029
T
GERP RS
5.5
Varity_R
0.15
gMVP
0.42
Mutation Taster
=92/8
polymorphism

Splicing

Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
0.0
Details are displayed if max score is > 0.2

Find out detailed SpliceAI scores and Pangolin per-transcript scores at spliceailookup.broadinstitute.org

Publications

Other links and lift over

dbSNP: rs144915346; hg19: chr14-102901135; API